CFDA:修改吗丁啉药品说明书 限用量

2016-09-16 leyna 赛柏蓝

前段时间,《这个药在美国是非法药物,中国人居然把它当成常备药!》一文一度在微信朋友圈刷屏,文中称“吗丁啉(化学名多潘立酮)”从未在美国上市,FDA 在其官方网站发出警告,建议停止使用该药。其他国家也有对多潘立酮药品的警示。不知道是否是舆论对多潘立酮药品安全性的质疑引发监管部门的关注,9月14日,国家食药监总局发布《关于修订多潘立酮制剂说明书的公告》,对多潘立酮非处方药和处方药的说明书进行了修改

前段时间,《这个药在美国是非法药物,中国人居然把它当成常备药!》一文一度在微信朋友圈刷屏,文中称“吗丁啉(化学名多潘立酮)”从未在美国上市,FDA 在其官方网站发出警告,建议停止使用该药。其他国家也有对多潘立酮药品的警示。


不知道是否是舆论对多潘立酮药品安全性的质疑引发监管部门的关注,9月14日,国家食药监总局发布《关于修订多潘立酮制剂说明书的公告》,对多潘立酮非处方药和处方药的说明书进行了修改。


国外和多潘立酮相关的警示


据《健康时报》在《这个药在美国是非法药物,中国人居然把它当成常备药!》一文中,表示,2007年,吗丁啉于1985年在加拿大上市,加拿大卫生部发布了9例与多潘立酮相关的心律失常报告,包括心律不齐、房颤、室性心动过速、心动过缓、心悸、QT间期延长和扭转型室性心动过速等,患者年龄范围为2个月至74岁。


2015年,加拿大卫生部更加肯定风险相关性,称多潘立酮会小幅增加严重室性心律失常或心源性猝死的风险。加拿大卫生部再次建议,开始应先以尽可能小的剂量用药,建议每日剂量不超过30mg,疗程越短越好。


2014年4月,欧洲药品管理局(EMA)发布报告,认为多潘立酮与严重心脏疾病风险相关,建议在整个欧盟范围内限制其适应症,仅用于缓解恶心和呕吐症状,不再用于治疗其他适应症如胀气或烧心,并建议在成人和体重超过35kg的青少年中将剂量减小至10mg,每日最多3次,使用不应超过1周。


国家局:调限制吗丁啉用量,增加心脏不良反应的警示


国家局对多潘立酮药品说明书修改增加了不良反应、禁忌等内容,也应该有所参考书加拿大、欧盟的警示,其中,在使用量上,成人一日3次,一次10mg,每日不得超过40mg;35kg以下儿童每日口服最多三次,每次0.25mg/kg体重;35kg以上儿童每日口服最多三次,每次10mg。用药3天,症状未缓解,请咨询医师或药师。药物使用时间一般不得超过1周。


在不良反应中也增加了和心脏疾病相关的内容。增加“有报道日剂量超过30毫克和/或伴有心脏病患者、接受化疗的肿瘤患者、电解质紊乱等严重器质性疾病的患者、年龄大于60岁的患者中,发生严重室性心律失常甚至心源性猝死的风险可能升高”的内容。


附:多潘立酮制剂非处方药说明书修订要求


现将多潘立酮口腔崩解片非处方药说明书范本修订要求公布如下:


一、【不良反应】:


“3.有研究提出日剂量超过30毫克以及年龄大于60岁的患者中,发生严重室性心率失常或心源性猝死的风险可能升高。”修改为:“3.有报道日剂量超过30毫克和/或伴有心脏病患者、接受化疗的肿瘤患者、电解质紊乱等严重器质性疾病的患者、年龄大于60岁的患者中,发生严重室性心律失常甚至心源性猝死的风险可能升高。”


二、【禁忌】:


(一)“1.机械性梗阻、胃肠道出血、胃肠道穿孔患者禁用。”修改为“1.机械性消化道梗阻,消化道出血、穿孔患者禁用。”


(二)“3.禁止与酮康唑口服制剂合用。”修改为“3.禁止与酮康唑口服制剂、红霉素或其他可能会延长QTc间期的CYP3A4酶强效抑制剂(例如:氟康唑、伏立康唑、克拉霉素、胺碘酮、泰利霉素)合用。”


(三)增加“4.中重度肝功能不全的患者禁用。”


三、【注意事项】:


(一)增加“1.本品用药3天,症状未缓解,请咨询医师或药师。药物使用时间一般不得超过1周。”


(二)删除“2.建议儿童使用多潘立酮混悬液。” 


(三)“3.由于多潘立酮主要在肝脏代谢,故肝功能损害的患者慎用。”修改为“5.由于多潘立酮主要在肝脏代谢,故肝生化指标异常的患者慎用。”


(四)“5.心脏病患者(如心律失常、充血性心衰等)以及接受化疗的肿瘤患者、电解质明显紊乱的患者应用时需慎重,有可能加重心律紊乱。”修改为“2.心脏病患者、接受化疗的肿瘤患者、电解质紊乱的患者应用时需慎重,有可能加重心律紊乱。”    


(五)增加“3.剧烈呕吐、急性腹痛患者应到医院就诊。”


(六)“6.老年患者应在医师指导下使用。”修改为“6.60岁以上的老年患者应在医师指导下使用。”


(七)其他项目编号顺延。


四、【药物相互作用】:


(一)“3.抗酸药和抑制胃酸分泌的药物可降低本品的生物利用度,不宜与本品同服。”修改为“3.抗酸药和抑制胃酸分泌的药物与本品同时使用可降低本品的生物利用度,建议间隔使用。”


(二)增加“5.与钙拮抗剂(如:地尔硫卓和维拉帕米)和阿瑞吡坦合用会导致多潘立酮的血药浓度升高。”


(三)其他项目编号顺延。


多潘立酮其他剂型的非处方药说明书参照口腔崩解片说明书进行修订,其中多潘立酮混悬液【用法用量】调整参见所附说明书范本。



多潘立酮制剂处方药说明书修订要求


一、【不良反应】:增加“有报道日剂量超过30毫克和/或伴有心脏病患者、接受化疗的肿瘤患者、电解质紊乱等严重器质性疾病的患者、年龄大于60岁的患者中,发生严重室性心律失常甚至心源性猝死的风险可能升高。”


二、【禁忌】应包含:


1)机械性消化道梗阻,消化道出血、穿孔患者禁用。


2)分泌催乳素的垂体肿瘤(催乳素瘤)、嗜铬细胞瘤、乳


癌患者禁用。


3)禁止与酮康唑口服制剂、红霉素或其他可能会延长QTc


间期的CYP3A4酶强效抑制剂(例如:氟康唑、伏立康唑、克拉霉素、胺碘酮、泰利霉素)合用。


4)中重度肝功能不全的患者禁用。


三、【用法用量】调整为:


成人一日3次,一次10mg,每日不得超过40mg;35kg以下儿童每日口服最多三次,每次0.25mg/kg体重;35kg以上儿童每日口服最多三次,每次10mg。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782851, encodeId=07a21e8285123, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Apr 14 21:02:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890598, encodeId=782c189059896, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 31 08:02:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146306, encodeId=6ec6146306eb, content=不错的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9b71604602, createdName=yushouqiang, createdTime=Wed Oct 12 08:49:27 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131183, encodeId=fc081311838c, content=知识无止境爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:46:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131182, encodeId=01f8131182e7, content=只是无止境,爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:45:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130627, encodeId=4a7313062e8d, content=很好的内容,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Mon Sep 19 05:19:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468537, encodeId=f5a1146853ea3, content=<a href='/topic/show?id=1b2e3915253' target=_blank style='color:#2F92EE;'>#吗丁啉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39152, encryptionId=1b2e3915253, topicName=吗丁啉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c73b6911859, createdName=bettycmoon, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507130, encodeId=38d6150e130f7, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628841, encodeId=9e3f1628841b9, content=<a href='/topic/show?id=57c38e486a2' target=_blank style='color:#2F92EE;'>#药品说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87486, encryptionId=57c38e486a2, topicName=药品说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8c21208991, createdName=fanweitanzhen, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129950, encodeId=f38712995051, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sun Sep 18 08:16:00 CST 2016, time=2016-09-18, status=1, ipAttribution=)]
    2017-04-14 doctorzheng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782851, encodeId=07a21e8285123, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Apr 14 21:02:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890598, encodeId=782c189059896, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 31 08:02:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146306, encodeId=6ec6146306eb, content=不错的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9b71604602, createdName=yushouqiang, createdTime=Wed Oct 12 08:49:27 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131183, encodeId=fc081311838c, content=知识无止境爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:46:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131182, encodeId=01f8131182e7, content=只是无止境,爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:45:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130627, encodeId=4a7313062e8d, content=很好的内容,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Mon Sep 19 05:19:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468537, encodeId=f5a1146853ea3, content=<a href='/topic/show?id=1b2e3915253' target=_blank style='color:#2F92EE;'>#吗丁啉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39152, encryptionId=1b2e3915253, topicName=吗丁啉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c73b6911859, createdName=bettycmoon, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507130, encodeId=38d6150e130f7, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628841, encodeId=9e3f1628841b9, content=<a href='/topic/show?id=57c38e486a2' target=_blank style='color:#2F92EE;'>#药品说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87486, encryptionId=57c38e486a2, topicName=药品说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8c21208991, createdName=fanweitanzhen, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129950, encodeId=f38712995051, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sun Sep 18 08:16:00 CST 2016, time=2016-09-18, status=1, ipAttribution=)]
    2017-01-31 stfoxst
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782851, encodeId=07a21e8285123, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Apr 14 21:02:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890598, encodeId=782c189059896, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 31 08:02:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146306, encodeId=6ec6146306eb, content=不错的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9b71604602, createdName=yushouqiang, createdTime=Wed Oct 12 08:49:27 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131183, encodeId=fc081311838c, content=知识无止境爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:46:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131182, encodeId=01f8131182e7, content=只是无止境,爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:45:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130627, encodeId=4a7313062e8d, content=很好的内容,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Mon Sep 19 05:19:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468537, encodeId=f5a1146853ea3, content=<a href='/topic/show?id=1b2e3915253' target=_blank style='color:#2F92EE;'>#吗丁啉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39152, encryptionId=1b2e3915253, topicName=吗丁啉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c73b6911859, createdName=bettycmoon, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507130, encodeId=38d6150e130f7, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628841, encodeId=9e3f1628841b9, content=<a href='/topic/show?id=57c38e486a2' target=_blank style='color:#2F92EE;'>#药品说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87486, encryptionId=57c38e486a2, topicName=药品说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8c21208991, createdName=fanweitanzhen, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129950, encodeId=f38712995051, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sun Sep 18 08:16:00 CST 2016, time=2016-09-18, status=1, ipAttribution=)]
    2016-10-12 yushouqiang

    不错的文献

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1782851, encodeId=07a21e8285123, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Apr 14 21:02:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890598, encodeId=782c189059896, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 31 08:02:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146306, encodeId=6ec6146306eb, content=不错的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9b71604602, createdName=yushouqiang, createdTime=Wed Oct 12 08:49:27 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131183, encodeId=fc081311838c, content=知识无止境爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:46:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131182, encodeId=01f8131182e7, content=只是无止境,爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:45:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130627, encodeId=4a7313062e8d, content=很好的内容,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Mon Sep 19 05:19:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468537, encodeId=f5a1146853ea3, content=<a href='/topic/show?id=1b2e3915253' target=_blank style='color:#2F92EE;'>#吗丁啉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39152, encryptionId=1b2e3915253, topicName=吗丁啉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c73b6911859, createdName=bettycmoon, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507130, encodeId=38d6150e130f7, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628841, encodeId=9e3f1628841b9, content=<a href='/topic/show?id=57c38e486a2' target=_blank style='color:#2F92EE;'>#药品说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87486, encryptionId=57c38e486a2, topicName=药品说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8c21208991, createdName=fanweitanzhen, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129950, encodeId=f38712995051, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sun Sep 18 08:16:00 CST 2016, time=2016-09-18, status=1, ipAttribution=)]
    2016-09-20 1e0d5b16m97(暂无匿称)

    知识无止境爱情恒久远

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1782851, encodeId=07a21e8285123, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Apr 14 21:02:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890598, encodeId=782c189059896, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 31 08:02:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146306, encodeId=6ec6146306eb, content=不错的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9b71604602, createdName=yushouqiang, createdTime=Wed Oct 12 08:49:27 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131183, encodeId=fc081311838c, content=知识无止境爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:46:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131182, encodeId=01f8131182e7, content=只是无止境,爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:45:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130627, encodeId=4a7313062e8d, content=很好的内容,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Mon Sep 19 05:19:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468537, encodeId=f5a1146853ea3, content=<a href='/topic/show?id=1b2e3915253' target=_blank style='color:#2F92EE;'>#吗丁啉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39152, encryptionId=1b2e3915253, topicName=吗丁啉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c73b6911859, createdName=bettycmoon, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507130, encodeId=38d6150e130f7, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628841, encodeId=9e3f1628841b9, content=<a href='/topic/show?id=57c38e486a2' target=_blank style='color:#2F92EE;'>#药品说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87486, encryptionId=57c38e486a2, topicName=药品说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8c21208991, createdName=fanweitanzhen, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129950, encodeId=f38712995051, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sun Sep 18 08:16:00 CST 2016, time=2016-09-18, status=1, ipAttribution=)]
    2016-09-20 1e0d5b16m97(暂无匿称)

    只是无止境,爱情恒久远

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1782851, encodeId=07a21e8285123, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Apr 14 21:02:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890598, encodeId=782c189059896, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 31 08:02:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146306, encodeId=6ec6146306eb, content=不错的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9b71604602, createdName=yushouqiang, createdTime=Wed Oct 12 08:49:27 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131183, encodeId=fc081311838c, content=知识无止境爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:46:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131182, encodeId=01f8131182e7, content=只是无止境,爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:45:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130627, encodeId=4a7313062e8d, content=很好的内容,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Mon Sep 19 05:19:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468537, encodeId=f5a1146853ea3, content=<a href='/topic/show?id=1b2e3915253' target=_blank style='color:#2F92EE;'>#吗丁啉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39152, encryptionId=1b2e3915253, topicName=吗丁啉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c73b6911859, createdName=bettycmoon, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507130, encodeId=38d6150e130f7, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628841, encodeId=9e3f1628841b9, content=<a href='/topic/show?id=57c38e486a2' target=_blank style='color:#2F92EE;'>#药品说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87486, encryptionId=57c38e486a2, topicName=药品说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8c21208991, createdName=fanweitanzhen, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129950, encodeId=f38712995051, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sun Sep 18 08:16:00 CST 2016, time=2016-09-18, status=1, ipAttribution=)]
    2016-09-19 lhl629

    很好的内容,谢谢分享。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1782851, encodeId=07a21e8285123, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Apr 14 21:02:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890598, encodeId=782c189059896, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 31 08:02:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146306, encodeId=6ec6146306eb, content=不错的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9b71604602, createdName=yushouqiang, createdTime=Wed Oct 12 08:49:27 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131183, encodeId=fc081311838c, content=知识无止境爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:46:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131182, encodeId=01f8131182e7, content=只是无止境,爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:45:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130627, encodeId=4a7313062e8d, content=很好的内容,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Mon Sep 19 05:19:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468537, encodeId=f5a1146853ea3, content=<a href='/topic/show?id=1b2e3915253' target=_blank style='color:#2F92EE;'>#吗丁啉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39152, encryptionId=1b2e3915253, topicName=吗丁啉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c73b6911859, createdName=bettycmoon, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507130, encodeId=38d6150e130f7, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628841, encodeId=9e3f1628841b9, content=<a href='/topic/show?id=57c38e486a2' target=_blank style='color:#2F92EE;'>#药品说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87486, encryptionId=57c38e486a2, topicName=药品说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8c21208991, createdName=fanweitanzhen, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129950, encodeId=f38712995051, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sun Sep 18 08:16:00 CST 2016, time=2016-09-18, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1782851, encodeId=07a21e8285123, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Apr 14 21:02:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890598, encodeId=782c189059896, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 31 08:02:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146306, encodeId=6ec6146306eb, content=不错的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9b71604602, createdName=yushouqiang, createdTime=Wed Oct 12 08:49:27 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131183, encodeId=fc081311838c, content=知识无止境爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:46:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131182, encodeId=01f8131182e7, content=只是无止境,爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:45:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130627, encodeId=4a7313062e8d, content=很好的内容,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Mon Sep 19 05:19:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468537, encodeId=f5a1146853ea3, content=<a href='/topic/show?id=1b2e3915253' target=_blank style='color:#2F92EE;'>#吗丁啉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39152, encryptionId=1b2e3915253, topicName=吗丁啉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c73b6911859, createdName=bettycmoon, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507130, encodeId=38d6150e130f7, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628841, encodeId=9e3f1628841b9, content=<a href='/topic/show?id=57c38e486a2' target=_blank style='color:#2F92EE;'>#药品说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87486, encryptionId=57c38e486a2, topicName=药品说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8c21208991, createdName=fanweitanzhen, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129950, encodeId=f38712995051, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sun Sep 18 08:16:00 CST 2016, time=2016-09-18, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1782851, encodeId=07a21e8285123, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Apr 14 21:02:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890598, encodeId=782c189059896, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 31 08:02:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146306, encodeId=6ec6146306eb, content=不错的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9b71604602, createdName=yushouqiang, createdTime=Wed Oct 12 08:49:27 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131183, encodeId=fc081311838c, content=知识无止境爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:46:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131182, encodeId=01f8131182e7, content=只是无止境,爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:45:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130627, encodeId=4a7313062e8d, content=很好的内容,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Mon Sep 19 05:19:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468537, encodeId=f5a1146853ea3, content=<a href='/topic/show?id=1b2e3915253' target=_blank style='color:#2F92EE;'>#吗丁啉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39152, encryptionId=1b2e3915253, topicName=吗丁啉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c73b6911859, createdName=bettycmoon, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507130, encodeId=38d6150e130f7, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628841, encodeId=9e3f1628841b9, content=<a href='/topic/show?id=57c38e486a2' target=_blank style='color:#2F92EE;'>#药品说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87486, encryptionId=57c38e486a2, topicName=药品说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8c21208991, createdName=fanweitanzhen, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129950, encodeId=f38712995051, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sun Sep 18 08:16:00 CST 2016, time=2016-09-18, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1782851, encodeId=07a21e8285123, content=<a href='/topic/show?id=a06c45212a' target=_blank style='color:#2F92EE;'>#CFDA:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4521, encryptionId=a06c45212a, topicName=CFDA:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Apr 14 21:02:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890598, encodeId=782c189059896, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 31 08:02:00 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146306, encodeId=6ec6146306eb, content=不错的文献, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9b71604602, createdName=yushouqiang, createdTime=Wed Oct 12 08:49:27 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131183, encodeId=fc081311838c, content=知识无止境爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:46:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131182, encodeId=01f8131182e7, content=只是无止境,爱情恒久远, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160820/IMG57B7D87F2AA596063.jpg, createdBy=c3e01933512, createdName=1e0d5b16m97(暂无匿称), createdTime=Tue Sep 20 07:45:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=130627, encodeId=4a7313062e8d, content=很好的内容,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Mon Sep 19 05:19:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468537, encodeId=f5a1146853ea3, content=<a href='/topic/show?id=1b2e3915253' target=_blank style='color:#2F92EE;'>#吗丁啉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39152, encryptionId=1b2e3915253, topicName=吗丁啉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c73b6911859, createdName=bettycmoon, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507130, encodeId=38d6150e130f7, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628841, encodeId=9e3f1628841b9, content=<a href='/topic/show?id=57c38e486a2' target=_blank style='color:#2F92EE;'>#药品说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87486, encryptionId=57c38e486a2, topicName=药品说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd8c21208991, createdName=fanweitanzhen, createdTime=Sun Sep 18 12:02:00 CST 2016, time=2016-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129950, encodeId=f38712995051, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Sun Sep 18 08:16:00 CST 2016, time=2016-09-18, status=1, ipAttribution=)]
    2016-09-18 1dd8a7c5m95(暂无匿称)

    学习了,赞一个!!!

    0

相关资讯

胃药“吗丁啉”到底还能不能吃

最近,各大媒体都以《这个药在美国是非法药物,中国人居然把它当成常备药!》为题进行报道和质疑“吗丁啉”的用药安全问题。作为药学专业人员,我觉得有必要针对这个报道厘清几个问题。 “吗丁啉” 存在安全问题吗? “吗丁啉” 药品通用名称为多潘立酮,属于促胃肠动力药。国内说明书适应症一项为治疗“消化不良、腹胀、嗳气、恶心、呕吐、腹部胀痛”。 该药的原研厂家是总部位于比利时的杨森制药。其安全性问题1

警惕,明星胃药吗丁啉,在美国被限制服用,中国人居然把它当常备药!

消化不良找吗丁啉帮忙”,这句在屏幕上活跃多年的广告语深入人心,也逐渐影响着国人用药习惯。然而,这款在国内被不少患者当做助消化药长期使用,在国外却多次被警示甚至建议限制使用。专家认为,以吗丁啉为代表的多潘立酮长时间大剂量使用有心脏方面风险,患者应更谨慎。  在国外屡遭警告多潘立酮是胃肠促动药,国内有不少企业生产。其中,西安杨森旗下的吗丁啉(商品名)是大家最熟知和常用的。不过,这种药在国外的日子并不好

胃动力药被限制使用,不只是吗丁啉!

很多人在大餐一顿后最容易出现的就是胃胀不适,习惯去药店买点药缓解一下,相信此时大家脑中想起的就是广告上经常出现的那个“胃”:胃部不适找吗丁啉帮忙。 然而这几天一则《这个药在美国是非法药物,中国人居然把它当成常备药》引爆了朋友圈(警惕,明星胃药吗丁啉,在美国被限制服用,中国人居然把它当常备药!),文中直指吗丁啉有巨大的副作用,能够引起心脏疾病,美国根本没有上市,多国也严加看管,而中国却作为非处方药